Driving Clinical Trials in Indonesia Through Strategic Collaborative Action
On November 13, 2025, in Jakarta, stakeholders from across the Western Pacific Region convened to accelerate the strengthening of the national clinical trial ecosystem in Indonesia. Supported by the WHO, the workshop included representatives from the Ministry of Health and the National Research and Innovation Agency (BRIN).
Expanding Clinical Research Capacity
The roadmap for modernization involves transitioning from single-country, small-scale academic studies to high-quality multi-country clinical trials. Key strategic pillars for 2026-2027 include:
- Regulatory Enablers: Streamlining ethics review processes and integrating research into routine clinical care.
- Phase 1 Readiness: Adopting initiatives similar to Malaysia's successful early-phase trial models.
- Workforce Development: Scaling up training for clinical trial units and professional investigators.
Piloting the clinical trial unit maturity framework to ensure international data standards.
Creating a sustainable ecosystem to attract pharmaceutical R&D and global CROs.
Strategic Partnership for Innovative Medicine
Discussions explored how WHO’s global frameworks can support Indonesia’s goal of increasing participation in trials for high-burden diseases and underrepresented populations. For industry leaders like ChemDiv, these advancements signify a more ethical, transparent, and robust environment for drug discovery and patient-centric research.
Together, these efforts aim to advance a resilient clinical trial ecosystem that delivers tangible health benefits across Indonesia and the Western Pacific Region.
